No Data
No Data
Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%
Here's Why We're Watching Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%
Prescient Therapeutics to Present PTX-100 Clinical Data at International T-cell Lymphoma Forum | ASX:PTX, OTC:PSTTF
Prescient Therapeutics Appoints Chair; Shares Fall 7%
Prescient Therapeutics Embarks on Board Chair Transition Process as Chair Retires | ASX:PTX, OTC:PSTTF